临床试验/IRCT20200105046010N88

IRCT20200105046010N88招募中Unknown

Bioequivalence study of Linagliptin 5mg tablet manufactured by Kharazmi Co versus originator brand (Trajenta) manufactured by Boehringer in fasting condition in healthy volunteers

Tabriz University of Medical Sciences0 个研究点目标入组 24 人开始时间: 待定最近更新: 2024年1月22日

试验速览

阶段: Unknown
状态: 招募中
发起方: Tabriz University of Medical Sciences
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 15 years 至 55 years（—）
性别: All

入选标准

•General Health (Liver, Heart, and Kidney)
•Body Mass Index (18-28)
•Informed consent
•Age (18-55 years old)

排除标准

•History of cardiovascular disease
•History of liver and kidney disease
•Alcoholism and Narcoticism
•History of allergy to Linagliptin

研究者

发起方

Tabriz University of Medical Sciences

相似试验

Comparative in vivo evaluation of 2 ?Linagliptin 5 mg Tablet formulations.Diabetes mellitus.Diabetes mellitus due to underlying condition

IRCT20180620040164N65Dorsa Pharmaceutical Co.24

Bioequivalence Study of 5 mg Linagliptin Film-coated Tablets in Healthy Thai VolunteersBioequivalence of generic linagliptin 5 mg film&#45coated tablets

TCTR20180213002All Research Co., Ltd.36

Comparative in vivo evaluation of 2 ?Linagliptin 5 mg Tablet formulations.Diabetes mellitus.Diabetes mellitus due to underlying condition

IRCT20180620040164N38Actover Pharmaceutical Co.24

igagliptin tablets 5mg ABIDI Pharmaceuticals (TRAJENTA® 5mg Tab) , In- Vivo Bioequivalence in Iranian healthy volunteers.

IRCT20200105046010N8Tabriz University of Medical Sciences24

Bioequivalence Study of Linagliptin/Metformin 2.5/1000 mg FC. Tablets of The Test Drug (Kharazmi Pharma, Iran)

IRCT20200105046010N101Kharazmi Pharmacy24